Autotaxin is a secreted glycoprotein 1 that acts as a lysophospholipase D (lysoPLD), converting lysophosphatidylcholine (LPC) into the lipid mediator lysophosphatidic acid (LPA) 2, 3 . LPA acts on specific G protein-coupled receptors to elicit responses that range from chemo taxis and neurite remodeling to cell proliferation and survival 4, 5 . The ATXLPA signaling axis has been implicated in vascular and neural development [6] [7] [8] [9] , tumor progression and metastasis [10] [11] [12] [13] [14] [15] , inflammation 16 , fibrotic disease 17,18 and neuropathic pain 19 . As such, ATX holds promise as an attractive and easily accessible therapeutic target. Potent smallmolecule inhibitors of ATX that can lower LPA in circulation have been described 20, 21 .
a r t i c l e s
Autotaxin is a secreted glycoprotein 1 that acts as a lysophospholipase D (lysoPLD), converting lysophosphatidylcholine (LPC) into the lipid mediator lysophosphatidic acid (LPA) 2, 3 . LPA acts on specific G protein-coupled receptors to elicit responses that range from chemo taxis and neurite remodeling to cell proliferation and survival 4, 5 . The ATXLPA signaling axis has been implicated in vascular and neural development [6] [7] [8] [9] , tumor progression and metastasis [10] [11] [12] [13] [14] [15] , inflammation 16 , fibrotic disease 17, 18 and neuropathic pain 19 . As such, ATX holds promise as an attractive and easily accessible therapeutic target. Potent smallmolecule inhibitors of ATX that can lower LPA in circulation have been described 20, 21 .
As a ~100kDa glycoprotein, ATX has several distinct domains (Fig. 1a) . At its N terminus it harbors two consecutive cysteinerich somatomedin B (SMB)like domains, which are known to be involved in proteinprotein interactions 22 . The ATX SMB domains are attrac tive candidates for mediating the demonstrated binding of ATX to activated platelets and lymphocytes in an integrindependent man ner 16, 23 , which might represent a possible route for localized LPA production and signaling at sites of injury and inflammation. The central catalytic phosphodiesterase (PDE) domain follows the SMB domains. It is similar to the catalytic domain of alkaline phosphatases, and its closest homolog with a known structure is a wellcharacterized bacterial phosphodiesterase 24 . Finally, at its C terminus, ATX contains a nucleaselike (NUC) domain, which is catalytically inert and pos sibly involved in substrate binding and presentation 25 .
ATX is one of seven mammalian ENPPtype ectophosphodieste rases 26 that contain central PDE domains. Owing to lack of structural data, the molecular basis for the diverse substrate preferences of ENPP family enzymes is not well understood. For example, the phospho diesterase activity of the founding member ENPP1, a protein that has been implicated in the etiology of mineralization diseases and diabetes, is nucleotideselective, whereas ATX preferentially hydrolyzes lyso phospholipids, although it also accepts nucleotides as substrates.
The most potent smallmolecule inhibitor of ATX contains a boronic acid, designed to specifically bind to the catalytic threonine of ATX 21 . A structurebased mechanistic understanding of how boron binds to the threonyl nucleophile and of the details of substrate recog nition and catalysis by ATX will accelerate the further development of selective ATX inhibitors.
To understand how the domains of ATX are organized, their role in determining selectivity for lipid over nucleotide substrates, how boronic acid inhibitors interact with ATX and how the integrin mediated interaction with platelets takes place, we determined the crystal structure of ATX. We here present the structure of ATX from rat (Rattus norvegicus) and the structurebased biochemical analysis of human ATX. a r t i c l e s
RESULTS
The crystal structure of ATX We determined the crystal structure of the fulllength secreted form of rat ATX, which is 93% identical to human ATX ( Supplementary  Fig. 1 ). Using HEK293 cells, we produced, purified and crystallized a variant of rat ATX, in which two of the three glycosylation sites were mutated to leave the single site needed for activity [27] [28] [29] . We determined the structure to 2.0 Å resolution by a combination of molecular replacement and singlewavelength anomalous dispersion ( Table 1) .
Rat ATX presents a compact and robust architecture for a multi domain protein (Fig. 1) ; two differently packed crystal forms show virtually identical domain placements (Fig. 1b,c) . The two Nterminal cysteinerich SMB domains and the Cterminal NUC domain contact opposing sides of the catalytic PDE domain. The structures of the individual domains of rat ATX (Fig. 1a) all resemble known folds (Fig. 2) . The Nterminal SMB domains are structurally similar to the SMB domains of vitronectin 22 and ENPP1 (PDB 2YSO, unpub lished data; Fig. 2a) . The catalytic PDE domain is most similar to the citrus bacterial pathogen Xanthomonas axonopodis nucleotide pyrophosphatase 24 (NPP; Fig. 2b) . The catalytic residues of ATX and NPP, including the catalytic Thr209 and Thr90, respectively, are also well conserved (Fig. 3a) . The closest structural match to the Cterminal NUC domain is the cyanobacterial nuclease NucA 30 ( Fig. 2c) , but none of the catalytic residues in NucA is conserved in the ATX NUC domain, which accounts for its catalytic inactivity.
The PDE-NUC domain interface
The PDE and NUC domains are tethered together in an unusually rigid manner. The interface area is 1,280 Å 2 , reinforced by seven hydro gen bonds and nine salt bridges. Many elements of the PDE domain participate in this interaction, whereas only the Cterminal region (residues 802-859) of the NUC domain is involved. The two domains are tethered by an intermolecular cysteine bridge between residues 413 and 805 (Fig. 1d) that is essential for retaining catalytic activity 25 . Moreover, a large 'lasso' loop of 50 residues (540-589), starting at the end of the PDE domain, wraps tightly around the NUC domain (Fig. 1c) , finally entering the fold from the side opposite to the PDE domain. The first two Nacetylglucosamine moieties of the essential Asn524linked glycan chain 27 are packed between the PDE and NUC domains (Fig. 1e) , forming an interface area of 321 Å 2 . Finally, the Cterminal region from residues 829 to 850, which is essential for secretion 25 , and Lys852, which is required for catalytic activity 25 , are also in the domain interface (Fig. 1f) . In the structure, Lys852 makes two salt bridges with Glu830 and Asp836 and is presumably important for positioning the Cterminal helix. It thus appears that evolution has selected for an extended range of interactions that bind the catalyti cally dead NUC domain to the active PDE domain.
The NUC domain of ATX (like those of ENPP1 and ENPP3) encom passes an EF hand-like (EFL) motif 26 ( 739 DYNYDGLRDTEDE 751 ) that is crucial for ENPP1 and ENPP3 activity 31 but, reportedly, not for ATX activity 32 . This 13residue EFL motif binds Ca 2+ (Supplementary Fig. 2a ) but is not flanked by helices. Notably, its first residue, Asp739, bridges to Lys430 and is the only residue out side the C terminus of the NUC domain that interacts with the PDE domain (Supplementary Fig. 2b) . ATX mutated at this site (K430A) was as active as the wildtype enzyme, but a considerable amount was retained intracellularly (Supplementary Fig. 2d) . Furthermore, the secreted fraction of the K430A mutant was more sensitive to thermal denaturation than wildtype ATX (Supplementary Fig. 2e) , suggesting that the salt bridge between Lys430 and Asp739 contrib utes to stabilization of the PDENUC interface. Mutation of three residues of the EFL motif (D739S, N741A and D743S) abolished the secretion of ATX (Supplementary Fig. 2d ). The mutant proteins that accumulated intracellularly showed strongly reduced activity (Supplementary Fig. 2e) 
a r t i c l e s
The phosphodiesterase catalytic site The PDE domains of ATX and X. axonopodis NPP 24 share similar archi tectures with fully conserved catalytic residues (Fig. 3) . At the active site (Fig. 3a,b) , the Zn 2+ ion proximal to the catalytic Thr209 (Thr210 in human ATX) is coordinated by the side chains of two aspartates and one histidine (Asp171, Asp358, His359), whereas the distal zinc is coordinated by one aspartate and two histidines (Asp311, His315 and His474). An asparagine residue (Asn230; Asn 231 in human ATX) faces the two metal ions in a position similar to that of Asn111 in X. axonopodis NPP. Asn111 in X. axonopodis NPP is not only important for catalysis but also confers specificity for phosphodiester bond hydrolysis 24 ; an arginine substitution at this position favored phosphatase activity. In human ATX, the N231A substitution markedly impairs the catalytic activity against both phospholipid and nucleotide substrates (Fig. 4a,b) . As ATX hydrolyzes ATP to generate AMP and pyrophosphate rather than ADP and phosphate, Asn230 is probably responsible for this preference for diester against monoester hydrolysis.
In one of the ATX crystal forms, we located a phosphate ion ( Fig. 3a  and Supplementary Fig. 3a ) that matches the positions occupied in X. axonopodis NPP-complex structures by the αphosphate of AMP or the transition state analog vanadate (Fig. 2b) . These similarities sug gest a conserved catalytic mechanism in which the activated Oγ nucleo phile of Thr209 attacks the phosphate group of a substrate, resulting in the formation of a transition state that involves a phosphate ester linkage 24 . The intermediate can then be hydrolyzed to LPA or AMP.
The substrate and inhibitor binding pocket ATX hydrolyzes both nucleotide and phospholipid substrates, at least in vitro. The location of the nucleotide binding site in ATX can be inferred from the structure of X. axonopodis NPP bound to AMP (Fig. 3f) . The shape of this site remains fully conserved in ATX (Fig. 3e) . These two enzymes, and other ENPP family members, are therefore expected to bind nucleotides in a similar manner.
ATXmediated hydrolysis of LPC is specifically and potently inhib ited by smallmolecule boronic acid inhibitors that lower plasma LPA levels in mice after intravenous administration 21 . We determined the structure of rat ATX in complex with one of these inhibitors, HA155 (ref. 33 ; Fig. 3c, Supplementary Fig. 3b ,c and Table 1 ), which enabled us to correlate the activity of this inhibitor with its binding mode and For the 'Native + I' and 'HA155 inhibitor' datasets, a single crystal was used. For the 'Native 2' dataset, two crystals were used. 
Anabaena nuclease Xa phosphodiesterase ATX phosphodiesterase ATX nuclease a r t i c l e s to make inferences about lipid substrate binding. The boron atom on one end of the inhibitor forms a reversible covalent bond with the nucleophile hydroxyl group of Thr209. One of the two boron hydroxyl groups is further stabilized between the two zinc ions. A search of the protein data bank did not yield any other structures in which a borate moiety is similarly complexed by two zinc ions and a threo nyl nucleophile 34 . The rest of the hydrophobic fourring system of HA155 forms an extended network of van der Waals contacts, with an interaction interface of 574 Å 2 . The first two aromatic rings of HA155 assume positions similar to those of the ribose and the adenine in the structure of X. axonopodis NPP bound to AMP (Fig. 3c,e) . The third ring, which is a thiazolidinedione, would not be accommodated by the X. axonopodis NPP structure (Fig. 3d) . The last aromatic ring, a hydrophobic fluorobenzene, points directly into a deep hydrophobic pocket that is perpendicular to the protein surface. We hypothesize that this hydrophobic pocket also binds the acyl chain of lysophospholipid substrates. We used high ambiguity-driven docking (HADDOCK 35 ) to create a model of the binding of LPC(14:0) to our structure of rat ATX. The acyl chain can be easily accommo dated in this pocket (Fig. 3g,h ). The model also shows that the pocket is large enough to accommodate only a single aliphatic chain, and explains how ATX sterically excludes diacyl phospholipids. Our model is consistent with previously reported biochemical data: for example, the change of Leu213 (Leu214 in human ATX)-one of the hydrophobic residues that lines the pocket and contacts the modeled tivity could provide useful tools for probing the biological role and significance of ATX in generating distinct molecular species of LPA.
Many of the binding cleft variants differentially affect LPC and nucle otide hydrolysis. Although all of them are less active in the LPC hydrolysis assay than the wild type, some can still hydrolyze nucleotide substrates with near wildtype activity. These include the previously reported L214H mutant and the mutants S170E, A218V and A305E (Fig. 4b) , which tar get the acyl chain lipidbinding region of the pocket. By contrast, the Y307Q or F211Y mutants, which target the region of the binding site that accommodates both nucleotides and lipids, are considerably less active against both lipid and nucleotide substrates. In fact, these two variants are comparatively less active against nucleotides than lipids, possibly because these mutations have a greater effect on the bulkier nucleoside moiety than the glycerol group of the lipid substrates. These observations suggest that the hydrophobic binding pocket is an extension of the nucleotide binding site that specifically accommodates lysophospholipid acyl chains without affecting nucleotide binding.
When the structures of ATX and X. axonopodis NPP are super imposed, a stretch of 18 amino acids in X. axonopodis NPP occu pies the space corresponding to the hydrophobic binding pocket of ATX (Fig. 2b) . Sequence alignments indicate that whereas ATX has a deletion in this region, X. axonopodis NPP and ENPP1 do not (Supplementary Fig. 1 ). The presence of this stretch of amino acids in ENPP1 and X. axonopodis NPP therefore explains why they cannot hydrolyze lysophospholipids, and why ENPP1 is insensitive to ATX inhibitors such as HA155 (ref. 21,33 ). substrate-to a polar histidine has been shown to decrease hydrolysis of LPC 36 . To validate our model further, we con structed additional binding site mutants and examined their activity (Fig. 4) . These mutagenesis studies used human ATX (resi due numbers in the human enzyme are n + 1 compared to the rat enzyme above, owing to a single residue insertion after residue 37). We used human ATX and catalytically inactive human ATX T210A as controls to evaluate the activity of the hydrophobic binding pocket mutants F211A, Y307Q, L214H, F275Q, A305E, F274E, A218V and S170E (Fig. 4a) . All mutants were expressed at levels similar to the wildtype enzyme. They were quanti fied and assayed in an LPC hydrolysis assay using saturating concentrations of LPC(14:0), the optimal substrate in vitro (Fig. 3c) . All of these hydrophobic pocket mutants showed reduced lysoPLD activity levels when com pared to wildtype human ATX (Fig. 4b) .
The A218V mutant, which has about half the activity of human ATX, targets a residue deep in the hydrophobic pocket and alters LPC selectivity (Fig. 4a) . This mutant hydro lyzes shortchain LPCs more efficiently than the wildtype protein (Fig. 4c) . This can be explained by the presence of a bulkier valine residue at the bottom of the pocket, which possibly mediates a better contact with, for example, LPC(12:0), but excludes substrates with longer acyl chains. A218V and similar mutations that alter the acyl chain length selec a r t i c l e s
The SMB domains and interaction with integrins
The two Nterminal cysteinerich SMB domains in ATX (atxSMB1 and atxSMB2) provide the first structural instances of these domains in the context of an intact protein. The structure of the SMB domain of the plasma protein vitronectin (vSMB) is known, both alone and in complex with the plasminogen activator inhibitor1 (PAI1, ref. 37 ; Fig. 5a ) and the urokinasetype plasminogen activator 38 (uPAR; Fig. 5b) . The struc tural organization of the SMB domain cysteine knot fold, which comprises four pairs of crossed disulfide bonds, had been the subject of consider able debate 22, 39 . The organization of the atxSMB domains is consistent with the vitronectin SMB Xray and NMR structures, as well as with the NMR structure of the ENPP1 SMB domain (PDB 2YS0, unpublished data).
Both atxSMB domains form extensive interactions with the catalytic PDE domain (Fig. 5c-e) . The interaction between the atxSMB1 domain and the PDE domain involves approximately the same surface as the one that mediates the interactions between vSMB and PAI1 or uPAR. However, atxSMB2 uses an unusual interface for interaction with the PDE domain, leaving the surface more typically used for protein protein interactions available to engage with other binding partners (Fig. 5d) . We tested whether human ATX could interact with PAI1 by coexpression and immuno precipitation experiments but detected no interaction (Supplementary Fig. 4) .
ATX binds to activated platelets in a β3 integrin-dependent manner and mediates static adhesion of platelets to immobilized ATX 23 . By analogy with the wellcharacterized vSMBmediated interactions with integrins, we considered the possibility that the ATX SMB domains also interact with platelet integrins. We found that a truncated protein containing only the two ATX SMB domains (residues 53-143, atxSMB) bound strongly to activated human platelets (Fig. 5f,g ). Binding to the SMB domains is enhanced by stimulating the platelets with ADP or the integrin activator Mn 2+ and is substantially a r t i c l e s attenuated by the β3 integrin-blocking antibody 7E3 (Fig. 5f) . Moreover, binding of the isolated SMB domains to platelets is com parable to that of fulllength ATX, in both avidity and concentration dependence (Supplementary Fig. 5a ). From these results we conclude that the Nterminal SMB domains are the primary mediators of the ATXplatelet interaction with β3 integrins on the agoniststimulated platelet surface.
The atxSMB2 domain contains within it an integrinbinding sequence RGD motif (residues 127-129, Fig. 5d,e) , whereas the vitronectin RGD motif is located several residues downstream from its SMB domain and is disordered 37 . In vitronectin, an RGD to RGE substitution disrupts an aspartic acid-mediated Mn 2+ interaction between the ligand and integrin and thereby severely attenuates integrin binding. However, an ATX RGE mutant (D129E) showed binding to activated platelets that was indistinguishable from that of wildtype ATX ( Supplementary  Fig. 5b) . Binding of platelets to the isolated SMB domains that con tained an AGA mutant (R127A and D129A) was lower than that of the wildtype SMB domain protein (Fig. 5g and Supplementary Fig. 6 ) but did not abolish it as expected. This suggested that the interaction of ATX with platelet β3 integrins is mechanistically distinct from the binding of the vitronectin SMB domain to these receptors and involves residues separate from the RGD motif. To investigate this notion further, we created five additional mutants of the atxSMB2 domain: E110A, R112A, H119A, E122A and D123A. Of these, H119A and E122A were expressed in amounts sufficient for purification and further experiments. Although E122A abrogated binding to an extent similar to that of the AGA mutant, the H119A mutant showed con siderably more reduced binding. Glu122 is conserved in the vSMB, whereas His119 is a glutamine (maintaining the nitrogen donor at a similar position), and both these residues participate in the interac tion of vSMB with PAI1 and uPAR. These experiments confirm that binding of ATX to integrins involves a wider portion of the available atxSMB2 surface, which includes His119, Asp122 and Asp129.
The SMB domains are involved in LPA binding AtxSMB1 abuts the lipidbinding pocket and a nearby narrow tunnel (the 'white hole' in Fig. 3h) . In both crystal forms, residual electron density occupies this tunnel (Supplementary Fig. 7) , probably indicat ing the presence of a molecule that we were unable to model (possibly a lipid acquired from the growth medium). The proximity of the SMB domains to the lipidbinding site and the tunnel raises the possibility that they might be involved in product binding and release.
To test whether the SMB domains modulated the enzymatic activity of ATX, we expressed an ATX variant lacking both SMB1 and SMB2 (∆SMBATX; residues 145-863 of human ATX). LPA acts as a mixed type inhibitor of ATX activity against a variety of substrates 40 . We could therefore investigate the role of the SMB domains in product binding and release by comparing LPAmediated inhibition of nucle otide hydrolysis in wildtype ATX and ∆SMBATX. Wildtype ATX and the ∆SMBATX protein showed similar activity against the classi cal nucleotide substrate pnitrophenyl thymidine 5′monophosphate (PNPTMP), with K M values of 1.93 ± 0.20 and 2.87 ± 0.9 mM, respec tively (Supplementary Fig. 8 ). However, whereas wildtype ATX activity against this substrate was potently inhibited by LPA(18:1) (EC 50 0.08 µM), ∆SMBATX was approximately tenfold less sensi tive (EC 50 0.72 µM) to inhibition by this LPA species (Fig. 4d) . These results identify a role for the SMB domains as a determinant of the affinity of the interaction between ATX and LPA, and are consistent with our suggestion that SMB1 participates in substrate recognition or product release. Processes that influence the interaction between SMB2 and the PDE domain-for example, integrin binding-could constitute a mechanism for physiological regulation of ATX activity.
DISCUSSION
We have determined the crystal structure of rat ATX and tested the activities of structurally guided sitedirected mutants in human ATX. As the enzymes from the two species are 93% identical, the biochemical and structural experiments readily complement one another. A deep, hydrophobic pocket of the type observed in ATX is a thermodynami cally unstable structure. We suggest that the formation of strong inter actions between the NUC and PDE domains during the course of evolution might have stabilized the fold sufficiently for it to accom modate the deletion of eighteen residues (Supplementary Fig. 1 ) and the consequent formation of the hydrophobic pocket.
The determinants of the substrate specificity of the ENPPs have long been unknown. The ATX structure provides a possible expla nation. Both nucleotides and lipids partially share the same binding pocket, but the acyl chain of lipid substrates form additional hydro phobic contacts with ATX. This model implies that the LPA product probably has higher affinity for ATX than any nucleotide substrate. This hypothesis is consistent with the finding that LPA acts as an inhibitor of ATX activity against a variety of substrates 40 , but not of LPC hydrolysis 33 . Thus, LPA formed by the enzyme may act as a 'substratespecifying factor' that effectively inhibits the hydrolysis of nucleotides because it can be displaced only by lysophospholipid substrates such as LPC. This mechanism could dictate ATX activity in vivo, because the spectrum of available LPA species could define ATX activity against specific lysophospholipid substrates. Our find ings also suggest that further analysis of structural determinants of substrate discrimination could lead to the identification of molecules that inhibit the hydrolysis of specific substrates; for example, long chain rather than shortchain LPC species.
The ATX SMB domains function as protein interaction modules, mediating platelet interaction through integrin binding. However, the binding mode seems to be structurally distinct from classical RGD mediated integrin binding. Instead, ATXSMB2 might interact with integrins using a surface similar to that used by the related vitronectin SMB domains in their interactions with PAI1 and uPAR.
We also have shown that the SMB domains are important for bind ing the LPA product to ATX, and we speculate that they might be involved in LPA release. In this scenario, SMBmediated interactions with integrins might not only provide a mechanism for recruiting ATX to the cell surface to generate LPA close to its receptors, but these interactions could also mediate a conformational change to pro mote product release. Localized LPA production by integrinmediated recruitment of ATX (for example, at the platelet surface) might account for the observed increase in plasma LPA levels after platelet activation 41 . Similar reasoning can also be applied to ENPP1, where a natural mutation of lysine 173 (K173Q, often described in the lit erature as 'K121Q') that is equivalent to the Arg128 of the ATX RGD motif has severe physiological consequences 42 , which suggests that modulation of integrin binding to the SMB domains through such mutations may result in altered ENPP1 or ENPP2 activities in vivo. Further structural and biochemical studies of ATX with its physiologi cal substrates, products and specific integrin subunits will be neces sary to unravel how exactly LPA production is regulated by ATX.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Protein Data Bank: The models and structure factors for rat ATX and rat ATX+HA155 are deposited with accession codes 2XR9 and 2XRG, respectively.
ONLINE METHODS
Protein production, crystallization and diffraction data collection. All proto cols are previously described 28, 29 . The HA155 inhibitor was mixed in threemolar excess with rat ATX and cocrystallized in conditions similar to those for the native data form 28 .
Structure solution and refinement. Crystallographic statistics are shown in Table 1 . The ATX structure was solved using PHASER 43 in the hybrid molecu lar replacement-single anomalous dispersion mode. We used the structure of X. axonopodis NPP (2GSN 24 ) as a search model, with nonconserved side chains truncated to the last common atom between residues. A clear rotation function solution was obtained (Z score = 15.01), sufficient to orient the single molecule of the asymmetric unit in the P1 space group. Using the phase probability dis tribution from that solution, PHASER identified ten heavy atom sites, using the anomalous differences from the zinc and iodine ions, resulting in phases with a 0.4 figure of merit. Solvent flattening followed by automated model building with ARP/wARP 44 resulted in 737 residues distributed in 8 chains. The model was completed manually using COOT 45 , interspersed with reciprocal space refine ment cycles in REFMAC5 (ref. 46 ). The final model was validated using the MolProbity 47 server, and is of excellent quality without any Ramachandran out liers, ranking in the 93 rd best percentile of PDB structures for that resolution. The second native crystal form, crystallized without iodine, was solved by molecular replacement and refined; apart from minor differences in disordered regions, the two models are identical. The HA155 complex was determined by molecu lar replacement using the native ATX model without ions; the difference map showed clear electron density for the omitted zinc ions and the HA155 ligand. This structure was refined with autoBUSTER 48 . After adjusting protein regions, HA155 was modeled and refined using a dictionary generated by PRODRG 49 and manually adjusted to conform to the tetrahedral geometry expected for the reversibly covalentbound boron atom. The ATXHA155 model was validated with Molprobity and showed 96.2% of all residues in Ramachandranfavored regions, ranking in the 100 th percentile for that resolution.
Structure analysis. Structural similarity searches were done with SSM 50 , using default parameters. All interface calculations were made with PISA 51 . The reported interface area is the difference in the accessible surface of isolated and interacting structures, divided by two.
The HADDOCK web server was used 35 for docking a flexible LPC molecule into the structure of rat ATX. The phosphate atom was restrained to a position consistent with that of the observed phosphate in the AMP-X. axonopodis NPP complex. The binding pocket residues that were in contact with the HA155 inhib itor were treated as 'active' residues that make contacts with the LPC substrate. All other parameters were used with default values. The docking experiment resulted in a single cluster of 200 structures.
Site directed mutagenesis. All constructs were made using standard molecular biology procedures and verified by sequencing.
Protein production for EF-hand mutants. Cells were transiently transfected at 30-40% confluency using FuGENE (Promega). The medium was collected 72 h later and the cells were lysed in 50 mM TrisHCl, pH 7.5, 150 mM NaCl, 1% (w/v) Triton X100 supplemented with 0.5 mM PMSF and 0.5 mM benzamide. After three freezethaw cycles and ultracentrifugation (30 min at 100,000g), the supernatant was collected and used as 'cell lysate' in western blots and to determine NPP2 activity.
Protein production for binding site mutants. HEK293 cells were transiently transfected at 30-40% confluency using FuGENE6. The medium was collected 96 h later and used for PNPTMP assays and LPC assays. Protein levels were quantified by western blot analysis.
ATX-lysoPLD activity assay. ATX lysoPLD activity was measured by the release of choline from LPC 21 . Briefly, medium from transfected HEK293 cells con taining approximately 5 nM human ATX (quantified by western blot analysis using purified wildtype ATX as a standard) was incubated with 500 µM LPC species in TrisHCl buffer (pH 7.4), 0.01% (w/v) Triton X100 for 4 h at 37 C. Liberated choline was detected colorimetrically using choline oxidase (1 unit mL −1 ), horseradish peroxidase (2 unit mL −1 ) and homovanillic acid (HVA) (2 mM). Fluorescence was determined at λ ex /λ em = 320/450nm in 96well plates.
Nucleotide phosphodiesterase assay. ATX nucleotide phosphodiesterase activ ity was measured colorimetrically using the nucleotide derivative PNPTMP as a substrate 40 . 15 nM human ATX of the medium used for the lysoPLD assay above was incubated with 1 mM PNPTMP in glycinebuffered saline at pH 9.5 in 96well plates. The amount of liberated pnitrophenolate (PNP) was deter mined by the absorbance at 405 nm for 3 h. LPA inhibition was investigated using incubations containing 0.01% (w/v) Triton X100 and varying concentrations of LPA(18:1).
Protein production for platelet binding assays and LPA inhibition experiments. ATX proteins were generated by expression in CHO cells using variants of pSecTag engineered to fuse an IgK leader sequence and furin protease site N terminus of a hexahistidine sequence. Secreted proteins were purified from con ditioned medium and concentrated to ~1 mg ml −1 for use in binding assays.
Static platelet adhesion assays. The interaction of ATX with activated platelets was studied by measuring binding of calceinlabeled platelets to fibrinogen, ATX or ATX fragments, using a microtiter plate assay as described previously 23 . In brief, human platelets were isolated from citrateanticoagulated blood. Platelets were labeled by incubation with 7 µg ml −1 calceinAM and 150 nM PGI2 and then isolated by gel filtration using Sepharose 2B eluted with Tyrode's buffer (12 mM NaHCO 3 , 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 10 mM HEPES, 0.35% (w/v) fattyacidfree BSA, pH 7.35). ATX, ATX fragments or fibrinogen were diluted in 50 mM Tris pH 7.4 100 mM NaCl and incubated in a Microfluor 96well plate for 16 h at 4 °C. The wells were washed and blocked by incubation with buffer for 1 h at room temperature. Gel filtered platelets were diluted to 200,000 ml −1 in Tyrode's buffer containing 2 mM CaCl 2 , 1 mM MgCl 2 (or 50 µM MnCl 2 as indicated) and platelet activators, small molecule inhibitors or blocking antibodies. After incubation for 60 min at room temperature, wells were washed with Tyrode's buffer containing 2 mM CaCl 2 and 1 mM MgCl 2 , (or 50 µM MnCl 2 as indicated) and bound platelets were quantified by measuring calcein fluorescence.
